Abstract
Background: Nomilin shows anti-inflammatory activity by inhibiting the activation of the Toll-like receptor 4 (TLR 4)/NF-κB pathway. However, the key target of the anti-inflammatory activity of nomilin has not been elaborated and needs further exploration.
Objective: This study aimed to assess the drug potential of nomilin and its ability to target myeloid differentiation protein 2 (MD-2) as a mechanism underlying the anti-inflammatory activity of nomilin on the lipopolysaccharide (LPS)-TLR4/MD-2-NF-κB signaling pathways.
Methods: The methods of ForteBio and molecular docking were used to investigate the internation between MD-2 and nomilin. 3-(4,5)-Dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide experiment was performed to test the effect of nomilin on cell viability. Enzyme-linked immunosorbent assay, real-time polymerase chain reaction, and Western blot experiments were carried out to assess the anti-inflammatory activity and possible mechanism of nomilin in vitro.
Results: The results indicated that nomilin exhibited binding affinity with MD-2. Nomilin significantly reduced the release and expression of NO, IL-6, TNF-α, and IL-1β induced by LPS in vitro. It inhibited the expression of LPS-TLR4/MD-2-NF-κB signaling pathway proteins, such as TLR4, Myd88, P65, P-P65, and iNOS.
Conclusion: Our results suggested that nomilin had therapeutic potential and was bound to MD-2. Nomilin exhibited anti-inflammatory activity by binding to the key protein MD-2 and inhibiting the LPS-TLR4/MD-2-NF-κB signaling pathway.
[http://dx.doi.org/10.1111/j.1365-2621.1985.tb13290.x]
[http://dx.doi.org/10.1111/j.1365-2621.1984.tb13209.x]
[http://dx.doi.org/10.1055/s-2003-45099] [PMID: 14648393]
[http://dx.doi.org/10.1016/j.ejphar.2011.07.029] [PMID: 21839074]
[http://dx.doi.org/10.1073/pnas.1424980112] [PMID: 26106158]
[http://dx.doi.org/10.1007/s10753-014-0042-8] [PMID: 25342286]
[PMID: 11581570]
[http://dx.doi.org/10.1016/j.smim.2003.10.007] [PMID: 14751758]
[http://dx.doi.org/10.1016/j.bcp.2012.11.002] [PMID: 23142712]
[http://dx.doi.org/10.1084/jem.20031076] [PMID: 14517279]
[http://dx.doi.org/10.1038/ni809] [PMID: 12055629]
[http://dx.doi.org/10.2174/1568010054526322] [PMID: 16101529]
[http://dx.doi.org/10.1038/nri1733] [PMID: 16322748]
[http://dx.doi.org/10.1007/s00011-008-8007-8] [PMID: 19109745]
[http://dx.doi.org/10.1016/0165-6147(91)90526-X] [PMID: 1712138]
[http://dx.doi.org/10.1016/j.ejphar.2015.08.040] [PMID: 26318197]
[http://dx.doi.org/10.1172/JCI11830] [PMID: 11134171]
[http://dx.doi.org/10.4049/jimmunol.166.4.2705] [PMID: 11160335]
[http://dx.doi.org/10.1038/sj.onc.1209934] [PMID: 17072322]
[http://dx.doi.org/10.1002/art.1780380202] [PMID: 7848304]
[http://dx.doi.org/10.1016/j.biocel.2008.05.005] [PMID: 18571461]